BRPI0517268A - método para tratar uma forma de leucemia linfocìtica crÈnica - Google Patents

método para tratar uma forma de leucemia linfocìtica crÈnica

Info

Publication number
BRPI0517268A
BRPI0517268A BRPI0517268-3A BRPI0517268A BRPI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A
Authority
BR
Brazil
Prior art keywords
treating
lymphocytic leukemia
chronic lymphocytic
anxamycin
hsp10
Prior art date
Application number
BRPI0517268-3A
Other languages
English (en)
Inventor
Thomas J Kipps
Francis J Burrows
Adeela Kamal
Carlo E Prada
Januario E Castro
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of BRPI0517268A publication Critical patent/BRPI0517268A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

MéTODO PARA TRATAR UMA FORMA DE LEUCEMIA LINFOCìTICA CRÈNICA. Método novo de tratar leucemia linfocitica crónica pela administração de inibidores de HSP9O, particularmente ansamicinas, mais particularmente 1 7-alilamino- 1 7-demetoxigeldanamicina (1 7-AAG).
BRPI0517268-3A 2004-11-02 2005-11-02 método para tratar uma forma de leucemia linfocìtica crÈnica BRPI0517268A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62463804P 2004-11-02 2004-11-02
PCT/US2005/039816 WO2006050457A2 (en) 2004-11-02 2005-11-02 Methods and compositions for treating chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
BRPI0517268A true BRPI0517268A (pt) 2008-10-07

Family

ID=36319809

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517268-3A BRPI0517268A (pt) 2004-11-02 2005-11-02 método para tratar uma forma de leucemia linfocìtica crÈnica

Country Status (13)

Country Link
US (1) US20080280878A1 (pt)
EP (1) EP1814392A4 (pt)
JP (1) JP2008519031A (pt)
KR (1) KR20070085677A (pt)
CN (1) CN101072504A (pt)
AU (1) AU2005302000A1 (pt)
BR (1) BRPI0517268A (pt)
CA (1) CA2584266A1 (pt)
IL (1) IL182618A0 (pt)
MX (1) MX2007004893A (pt)
NO (1) NO20072190L (pt)
RU (1) RU2007120473A (pt)
WO (1) WO2006050457A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050333A2 (en) 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
CA2734428A1 (en) * 2008-08-18 2010-02-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Susceptibility to hsp90-inhibitors
WO2010033719A1 (en) 2008-09-17 2010-03-25 Sphingomonas Research Partners, L.P. Treatment for leukemia and idiopathic aplastic anemia
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1519735A4 (en) * 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2413475C (en) * 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
US7282493B2 (en) * 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof

Also Published As

Publication number Publication date
WO2006050457A3 (en) 2006-12-14
WO2006050457A2 (en) 2006-05-11
CN101072504A (zh) 2007-11-14
EP1814392A2 (en) 2007-08-08
RU2007120473A (ru) 2008-12-10
MX2007004893A (es) 2007-06-14
EP1814392A4 (en) 2008-06-11
NO20072190L (no) 2007-07-13
CA2584266A1 (en) 2006-05-11
US20080280878A1 (en) 2008-11-13
AU2005302000A1 (en) 2006-05-11
JP2008519031A (ja) 2008-06-05
IL182618A0 (en) 2007-07-24
KR20070085677A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
AR110313A2 (es) Derivados de tiazol-2-il-pirrolidina
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
MX2008009638A (es) Metodo y dispositivo para alimentar quimicos en una corriente de proceso.
EA200601457A1 (ru) Ингибиторы вирусной полимеразы
NO20082266L (no) Nye 1-azabicykloalkylderivater for behandling av psykotiske og neurodegenerative forstyrrelser
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
PL1633697T3 (pl) Sposób wytwarzania podstawionych związków 3-arylo-butylo-aminowych
TW200740761A (en) Histone deacetylase inhibitors
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
TW200505621A (en) Non-separating diffuser for holes produced by a two step process
TN2009000151A1 (en) Mapk/erk kinase inhibitors
MY145788A (en) Antitumoral dihydropyran-2-one compounds
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20060403L (no) Kjemiske forbindelser
CR8350A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica
MX2014000437A (es) Composicion para el control de plagas artropodas y metodo para controlarlas.
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
TW200619213A (en) A process for the preparation of organic compounds
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
MX2007004893A (es) Metodos y composiciones para el tratamiento de leucemia linfocitica cronica.
NO20061302L (no) Derivater av hydroksaminsyre som metalloproteinseinbitorer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.